Table 1.
Baseline characteristics of patients with IgAN and HCs
| Parameters | IgAN Group (n=127) | HC Group (n=127) | P Value | |
|---|---|---|---|---|
| Age (yr), mean±SD | 35.6±10.3 | 34.8±10.9 | 0.59 | |
| Male, n (%) | 76 (59.8) | 68 (53.3) | 0.31 | |
| BMI (kg/m2), mean±SD | 24.3±3.9 | 23.5±2.0 | 0.06 | |
| WBC (109/L), mean±SD | 6.7±1.8 | 6.1±1.4 | 0.001 | |
| Platelets (109/L), mean±SD | 235.1±75.6 | 229.9±50.1 | 0.52 | |
| Anemia, n (%) | 16 (12.6) | 2 (1.6) | 0.001 | |
| Albumin (g/L), mean±SD | 40.3±5.4 | 47.8±3.6 | 0.00 | |
| SCr (μmol/L), mean±SD | 104.0±39.7 | 72.1±15.1 | 0.001 | |
| eGFR (ml/min per 1.73 m2), mean±SD | 76.8±30.0 | 106.3±17.0 | 0.00 | |
| eGFR <60 ml/min per 1.73 m2, n (%) | 38 (29.9) | 0 (0.0) | 0.00 | |
| Hypertension, n (%) | 34 (26.8) | 0 (0.0) | 0.00 | |
| Proteinuria (mg/d), median (IQR) | 1070.0 (518.0–1760.0) | NA | ||
| Proteinuria >1.0 g/d, n (%) | 68 (53.8) | NA | — | |
| Cystatin C (mg/L), mean±SD | 1.23±0.46 | NA | ||
| Uric acid (μmol/L), mean±SD | 356.8±114.7 | NA | ||
| Serum urea (mmol/L), median (IQR) | 5.6 (4.5–7.9) | NA | ||
| Histologic lesion scoring, n (%) | ||||
| M1 | 75 (59.1) | |||
| E1 | 17 (13.4) | |||
| S1 | 98 (77.2) | |||
| T lesion scoring, n (%) | ||||
| T0 | 73 (57.5) | |||
| T1 | 35 (27.6) | |||
| T2 | 19 (15.0) | |||
| C lesion scoring, n (%) | ||||
| C0 | 84 (66.1) | |||
| C1 | 38 (29.9) | |||
| C2 | 5 (3.9) | |||
WBC, white blood cell; SCr, serum creatinine; IQR, interquartile range; NA, not available; M1, mesangial hypercellularity; E1, endocapillary hypercellularity; S1, segmental glomerulosclerosis; T, tubular atrophy/interstitial fibrosis; T0, T ≤25%; T1, T 26%–50%; T2, T >50%; C0, no crescents; C1, crescents in less than one fourth of glomeruli; C2, crescents in over one fourth of glomeruli.